IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32866-0.html
   My bibliography  Save this article

Potential solutions for manufacture of CAR T cells in cancer immunotherapy

Author

Listed:
  • Ulrich Blache

    (Fraunhofer Institute for Cell Therapy and Immunology (IZI)
    Fraunhofer Cluster of Excellence for Immune-Mediated Disease)

  • Georg Popp

    (Fraunhofer Institute for Cell Therapy and Immunology (IZI))

  • Anna Dünkel

    (Fraunhofer Institute for Cell Therapy and Immunology (IZI))

  • Ulrike Koehl

    (Fraunhofer Institute for Cell Therapy and Immunology (IZI)
    Fraunhofer Cluster of Excellence for Immune-Mediated Disease
    University of Leipzig)

  • Stephan Fricke

    (Fraunhofer Institute for Cell Therapy and Immunology (IZI)
    Fraunhofer Cluster of Excellence for Immune-Mediated Disease)

Abstract

CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Suggested Citation

  • Ulrich Blache & Georg Popp & Anna Dünkel & Ulrike Koehl & Stephan Fricke, 2022. "Potential solutions for manufacture of CAR T cells in cancer immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32866-0
    DOI: 10.1038/s41467-022-32866-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32866-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32866-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. J. Joseph Melenhorst & Gregory M. Chen & Meng Wang & David L. Porter & Changya Chen & McKensie A. Collins & Peng Gao & Shovik Bandyopadhyay & Hongxing Sun & Ziran Zhao & Stefan Lundh & Iulian Pruteanu, 2022. "Decade-long leukaemia remissions with persistence of CD4+ CAR T cells," Nature, Nature, vol. 602(7897), pages 503-509, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ariel Isser & Aliyah B. Silver & Hawley C. Pruitt & Michal Mass & Emma H. Elias & Gohta Aihara & Si-Sim Kang & Niklas Bachmann & Ying-Yu Chen & Elissa K. Leonard & Joan G. Bieler & Worarat Chaisawangw, 2022. "Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    2. Raymond Hall Yip Louie & Curtis Cai & Jerome Samir & Mandeep Singh & Ira W. Deveson & James M. Ferguson & Timothy G. Amos & Helen Marie McGuire & Kavitha Gowrishankar & Thiruni Adikari & Robert Balder, 2023. "CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    3. Dhivya Sridaran & Surbhi Chouhan & Kiran Mahajan & Arun Renganathan & Cody Weimholt & Shambhavi Bhagwat & Melissa Reimers & Eric H. Kim & Manish K. Thakur & Muhammad A. Saeed & Russell K. Pachynski & , 2022. "Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance," Nature Communications, Nature, vol. 13(1), pages 1-21, December.
    4. Tomás A. Martins & Deniz Kaymak & Nazanin Tatari & Fiona Gerster & Sabrina Hogan & Marie-Françoise Ritz & Valerio Sabatino & Ronja Wieboldt & Ewelina M. Bartoszek & Marta McDaid & Alexandra Gerber & A, 2024. "Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker," Nature Communications, Nature, vol. 15(1), pages 1-25, December.
    5. Ugur Uslu & Lijun Sun & Sofia Castelli & Amanda V. Finck & Charles-Antoine Assenmacher & Regina M. Young & Zhijian J. Chen & Carl H. June, 2024. "The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    6. Elisa Landoni & Mark G. Woodcock & Gabriel Barragan & Gabriele Casirati & Vincenzo Cinella & Simone Stucchi & Leah M. Flick & Tracy A. Withers & Hanna Hudson & Giulia Casorati & Paolo Dellabona & Piet, 2024. "IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    7. Rocío Castellanos-Rueda & Raphaël B. Roberto & Florian Bieberich & Fabrice S. Schlatter & Darya Palianina & Oanh T. P. Nguyen & Edo Kapetanovic & Heinz Läubli & Andreas Hierlemann & Nina Khanna & Sai , 2022. "speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    8. Jianting Long & Xihe Chen & Mian He & Shudan Ou & Yunhe Zhao & Qingjia Yan & Minjun Ma & Jingyu Chen & Xuping Qin & Xiangjun Zhou & Junjun Chu & Yanyan Han, 2024. "HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    9. Dan Li & Ruixue Wang & Tianyuzhou Liang & Hua Ren & Chaelee Park & Chin-Hsien Tai & Weiming Ni & Jing Zhou & Sean Mackay & Elijah Edmondson & Javed Khan & Brad St Croix & Mitchell Ho, 2023. "Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours," Nature Communications, Nature, vol. 14(1), pages 1-17, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32866-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.